Company Profile

Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Employees

154

Sector

Biotechnology & Medical Research

More about the company

07/12/22	MorphoSys Out Licenses Pre-Clinical Oncology Program	CI
17/07/21	MorphoSys : Royalty Pharma Takes Equity Position in MorphoSys for $100 Million	MT
15/07/21	Constellation Announces Management Changes	CI
15/07/21	Constellation Pharmaceuticals, Inc. Announces Resignation of Jigar Raythatha as Chief Executive Officer	CI
15/07/21	Constellation Pharmaceuticals, Inc. Announces Resignation of Emma Reeve as Chief Financial Officer	CI
15/07/21	DJ Industrial : Wall Street Futures Mostly Lower, Jobless Claims Drop Less Than Expected; Powell Speech Eyed	MT
15/07/21	MorphoSys : Finalizes $1.7 Billion Acquisition of Constellation Pharmaceuticals	MT
15/07/21	MorphoSys : Completes Tender Offer for Constellation Pharmaceuticals	MT
15/07/21	Constellation Pharmaceuticals, Inc.(NasdaqGM:CNST) dropped from NASDAQ Composite Index	CI
15/07/21	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P TMI Index	CI
15/07/21	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Biotechnology Select Industry Index	CI
15/07/21	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Global BMI Index	CI
15/07/21	MorphoSys AG completed the acquisition of Constellation Pharmaceuticals, Inc..	CI

17/06/21	CONSTELLATION PHARMACEUTICALS : RBC Capital Downgrades Constellation Pharmaceuticals to Sector Perform From Outperform, Price Target Cut to $34 From $50	MT
04/06/21	CONSTELLATION PHARMACEUTICALS : Jefferies Downgrades Constellation Pharmaceuticals to Hold From Buy, Adjusts Price Target to $34 From $53	MT
04/06/21	CONSTELLATION PHARMACEUTICALS : Truist Securities Downgrades Constellation Pharmaceuticals to Hold From Buy, Adjusts PT to $34 From $50	MT
03/06/21	CONSTELLATION PHARMACEUTICALS : BMO Capital Downgrades Constellation Pharmaceuticals to Market Perform from Outperform, Adjusts Price Target to $34 from $48	MT
03/06/21	CONSTELLATION PHARMACEUTICALS : JPMorgan Downgrades Constellation Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $34 from $38	MT

19/07/21	Royalty Pharma : MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma	AQ
17/07/21	MorphoSys AG :	AQ
15/07/21	Constellation Pharmaceuticals : Completion of Acquisition or Disposition of Assets (Form 8-K)	PU
15/07/21	CONSTELLATION PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
17/06/21	PRESS RELEASE : MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals	DJ

29/07/21	Morphosys macht mehr Umsatz - Operativer Verlust höher
29/07/21	Morphosys verbucht in 2Q dank Finanzerträgen Gewinn
27/07/21	AKTIE IM FOKUS 2: MorphoSys setzen Talfahrt fort - Commerzbank streicht 'Buy'
27/07/21	MÄRKTE EUROPA/Etwas leichter - Bitcoin mit Rally
26/07/21	XETRA-SCHLUSS/Leichte Abgaben zu Wochenbeginn - Morphosys brechen ein

Manager	Title	Age	Since
John McKenna PSD	President	-	-
Kia Khalaghpour IRC	Investor Relations Contact	-	-
Irina Apostolou PRN	Corporate Officer/Principal	-	01/08/2016

Constellation Pharmaceuticals, Inc. Stock

Stocks

CNST

US2103731061

Biotechnology & Medical Research

Latest news : Constellation Pharmaceuticals, Inc.

Analysts' recommendations: Constellation Pharmaceuticals, Inc.

Press Releases: Constellation Pharmaceuticals, Inc.

News in other languages: Constellation Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Constellation Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Director	Title	Age	Since
Kathleen Warnecke BRD	Director/Board Member	-	15/07/2021
John McKenna BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/07/21	Scott Braunstein	Issuer sale	Director	52,684	0.1098%
15/07/21	Patric Trojer	Issuer sale	Chief Technology Officer	365,758	0.7625%
15/07/21	Richard Levy	Issuer sale	Director	39,513	0.0824%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CONSTELLATION PHARMACEUTICALS, INC.	+0.06%	+0.12%	-	-	1.62B
ARGENX SE	+1.03%	+7.52%	+54.74%	+114.98%	55.58B
WUXI APPTEC CO., LTD.	+2.72%	+3.06%	+53.28%	+47.85%	43.47B
BIONTECH SE	+1.12%	+2.79%	-13.71%	-17.53%	22.64B
INSMED INCORPORATED	+1.17%	+3.85%	+1.00%	+401.79%	20.96B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-4.13%	+16.62%	-30.70%	15.79B
GENMAB A/S	+0.15%	+2.24%	+9.06%	-39.50%	15.3B
EXELIXIS, INC.	-0.69%	+0.82%	+27.17%	+178.31%	13.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+6.41%	+21.05%	-	11.74B
PHARMAESSENTIA CORPORATION	+1.61%	+1.17%	+90.79%	+212.97%	10.96B
Average	+1.62%	+0.26%	+28.89%	+108.52%	23.32B
Weighted average by Cap.	+1.69%	+1.60%	+33.72%	+101.64%